Semaglutide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 28 Jan 2019: Trial registered, NCT03819153
  2. 17 Jun 2019: Trial started, NCT03819153
  3. 28 Apr 2021: Trial started, NCT04865770
  4. 29 Apr 2021: Trial registered, NCT04865770
  5. 27 Mar 2023: Trial registered, NCT05786521
  6. 1 Apr 2023: Trial started, NCT05786521
  7. 29 Apr 2023: Trial started, NCT05870462
  8. 23 May 2023: Trial registered, NCT05870462

The trials

NCT03819153: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

State
Completed
Phase
Phase 3
People
3,533 taking part
Started
17 Jun 2019
Primary completion
9 Jan 2024
Arms
Semaglutide
Results
Posted on the registry
  1. 28 Jan 2019: Trial registered
  2. 17 Jun 2019: Trial started
  3. 9 Jan 2024: Trial completed
  4. 20 Mar 2025: Trial results posted

NCT04865770: A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

State
Completed
Phase
Phase 3
People
106 taking part
Started
28 Apr 2021
Primary completion
21 Nov 2024
Arms
Semaglutide 1.0 mg OW
Results
Posted on the registry
  1. 28 Apr 2021: Trial started
  2. 29 Apr 2021: Trial registered
  3. 21 Nov 2024: Trial completed
  4. 14 Jan 2026: Trial results posted

NCT05067621: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

State
Under way
Phase
Phase 2
People
60 taking part
Started
17 Jul 2023
Primary completion
Dec 2026
Arms
Receive treatment
Results
None posted
  1. 5 Oct 2021: Trial registered
  2. 17 Jul 2023: Trial started

NCT05786521: Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

State
Completed
Phase
Phase 4
People
20 taking part
Started
1 Apr 2023
Primary completion
20 May 2024
Arms
Semaglutide and lifestyle intervention
Results
Posted on the registry
  1. 27 Mar 2023: Trial registered
  2. 1 Apr 2023: Trial started
  3. 20 May 2024: Trial completed
  4. 4 May 2025: Trial results posted

NCT05870462: Semaglutide and Vascular Regeneration

State
State not given
Phase
Phase 4
People
100 planned
Started
29 Apr 2023
Primary completion
Dec 2024
Arms
Semaglutide
Results
None posted
  1. 29 Apr 2023: Trial started
  2. 23 May 2023: Trial registered

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
Semaglutide
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

NCT07374328: Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

State
Under way
Phase
Phase 1 and Phase 2
People
240 planned
Started
1 Jun 2025
Primary completion
31 May 2026
Arms
Semaglutide group: patients receive semaglutide treatment.
Results
None posted
  1. 1 Jun 2025: Trial started
  2. 28 Jan 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.